8 completed, 4 recruiting, 4 unknown, 4 withdrawn. 17 Phase 2, 7 Phase 1, 3 Not applicable, 3 Phase 3, 2 Early Phase 1.
Follow this drug Literature Review of Transplantation Conditioning trials Research Report on Transplantation Conditioning
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen - AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-07-20 | 2026-06-12 |
| Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy) - Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-06-04 |
| Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy) - Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-02-02 | 2026-03-18 |
| Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-12-30 | 2026-04-27 |
| Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Mobilization Regimen, Conditioning Regimen, GVHD Prophylaxis - ALS (Amyotrophic Lateral Sclerosis) | Not applicable | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 8 | 2025-12-29 | 2026-04-20 |
| Tolerance Through Mixed Chimerism (Sip-Tego) Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart) - Kidney Failure, Transplant Recipient (Kidney) | Early Phase 1 | Active not recruiting | Tatsuo Kawai, MD, PhD | 12 | 2025-05-31 | 2026-09-25 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | Withdrawn | National Cancer Institute (NCI) | 2023-08-10 | 2024-03-20 | |
| US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies ECT-001-CB (UM171-Expanded Cord Blood Transplant) - High Risk Myeloid Malignancies, Cord Blood Transplant | Phase 1 / Phase 2 | Completed | ExCellThera inc. | 13 | 2021-12-01 | 2026-03-24 |
| Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells - Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 33 | 2021-02-15 | 2026-02-17 |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) K-NK002, Conditioning Regimen, HaploBMT - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 2 | Withdrawn | Kiadis Pharma | 2020-11-13 | 2021-06-22 | |
| BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) Conditioning regimen with half-matched (haploidentical) stem cell transplant - Acute Leukemia, MDS | Phase 2 | Recruiting | University of Illinois at Chicago | 27 | 2020-01-27 | 2026-04-06 |
| Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT Cyclophosphamide, Anti-Thymocyte Globulin, Conditioning regimen - Graft vs Host Disease | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 94 | 2017-04-06 | 2020-11-20 |
| Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning - AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2016-06-22 | 2018-12-27 | |
| Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion Conditioning Regimen & GVHD Prophylaxis - Leukemia, Lymphoma | Phase 1 / Phase 2 | Withdrawn | Ann & Robert H Lurie Children's Hospital of Chicago | 2013-12-01 | 2019-08-30 | |
| Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Conditioning Regimen with Bone Marrow Transplant - Sickle Cell Disease | Phase 2 | Completed | Emory University | 22 | 2012-03-01 | 2017-11-21 |
| Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation Transplantation Conditioning for BMT - End Stage Renal Disease | Not applicable | Unknown | Samsung Medical Center | 6 | 2011-12-01 | 2014-07-24 |
| Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma Induction Phase, Consolidation Phase (on day +50), Intensification phase - HIV, Burkitt's Lymphoma | Phase 2 | Completed | Andres J. M. Ferreri | 19 | 2011-11-01 | 2022-08-04 |
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation - Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Regimmune Corporation | 68 | 2011-09-01 | 2019-10-23 |
| Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab - Severe Combined Immunodeficiency | Phase 2 | Terminated | University of California, San Francisco | 7 | 2010-08-01 | 2018-07-31 |
| Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Conditioning regimen, Graft-versus-host disease (GVHD) prophylaxis, Stem Cell Transplantation - Mucopolysaccharidosis | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 10 | 2009-09-01 | 2012-06-04 |
Showing 20 of 25. Sign in to see all of them.
Graft vs Host Disease (3) · Hematologic Neoplasms (3) · Myelodysplastic Syndromes (3) · Hematologic Diseases (2) · Kidney Failure, Chronic (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Amyotrophic Lateral Sclerosis (1) · Anemia (1) · Anemia, Sickle Cell (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1)
Beijing Biotech (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Tehran University of Medical Sciences (2) · Andres J. M. Ferreri (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Assistance Publique - Hôpitaux de Paris (1) · City of Hope Medical Center (1) · Emory University (1) · ExCellThera inc. (1) · Fred Hutchinson Cancer Center (1) · Heidelberg University (1) · Kiadis Pharma (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (12) · China (3) · Iran (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · South Korea (1)
A. Benedict Cosimi, MD (1) · Amir Ali Hamidieh, MD (1) · Anthony D. Ho, Ph.D., Prof. (1) · Christopher C Dvorak, M.D. (1) · David H. Sachs, MD (1) · Hans-Peter Kiem (1) · Ibrahim Aldoss (1) · Lakshmanan Krishnamurti, MD (1) · Reggie Duerst, MD (1) · Richard Champlin, MD (1) · Richard J Lin, MD, PhD (1) · Rondelli Damiano, MD (1)
PMID 18216355, PMID 33811823, PMID 38374026
2016 (1), P30CA015704 (1), P30CA033572 (1), R34HL108761 (1), U10CA180820 (1), U24HL138660 (1)